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Abstract
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Fatigue is a symptom associated with many disorders, is especially common in women and in
older adults, and can have a huge negative influence on quality of life. Although most past
research on fatigue uses human subjects instead of animal models, the use of appropriate animal
models has recently begun to advance our understanding of the neurobiology of fatigue. In this
review, results from animal models using immunological, developmental, or physical approaches
to study fatigue are described and compared. Common across these animal models is that fatigue
arises when a stimulus induces activation of microglia and/or increased cytokines and chemokines
in the brain. Neurobiological studies implicate structures in the ascending arousal system, sleep
executive control areas, and areas important in reward. In addition, the suprachiasmatic nucleus
clearly plays an important role in homeostatic regulation of the neural network mediating fatigue.
This nucleus responds to cytokines, shows decreased amplitude firing rate output in models of
fatigue, and responds to exercise, one of our few treatments for fatigue. This is a young field but
very important as the symptom of fatigue is common across many disorders and we do not have
effective treatments.
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Introduction
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Fatigue is one of the most common complaints that brings patients to see their clinician in
part because feeling unusually fatigued can dramatically impact quality of life. "Feeling
tired for no reason", a common report in people suffering from fatigue (Kirsh et al., 2001),
leads to reduced ability to work, to enjoy life, and to sleep well. Fatigue is a symptom
associated with illness, depression, and aging, and is reported as a primary symptom in
multiple sclerosis and Parkinson’s disease, post-stroke, and post-poliomyelitis. Fatigue is an
important symptom of frailty in aged populations (Fried et al., 2001) and predicts functional
limitation (Avlund et al., 2003a), disability (Avlund et al., 2003b) and mortality (Hardy and
Studenski, 2008, Moreh et al., 2010). In cancer patients fatigue is often experienced prediagnosis, can be a result from treatments, and can be a lasting problem even following cure
(Wang, 2011). A traumatic brain injury is often followed by lasting fatigue and sleep
disorders (Cantor et al., 2008). One would think that such an important and widely
experienced symptom would be extensively researched, since any insight into biological
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mechanisms could potentially lead to a treatment applicable to many populations. The
difficulty in defining fatigue and in developing animal models for the study of fatigue has
impeded progress in this field.
Researchers have found it hard to agree on a definition of fatigue. There are more than 250
self report measurement devices for assessing fatigue in human populations in the literature,
about 150 of these measurement scales apparently only used once (Hjollund et al., 2007).
Recent efforts to draw together a consensus definition and method for assessment of fatigue
promise to help advance this field (Barsevick et al., 2010). Even more importantly, several
animal models have been developed with common features, leading us to believe we are
coming to a consensus on the objective manifestation of a state of fatigue in a laboratory
animal. To make rapid progress in our understanding of this distressing symptom, animal
models will allow controlled studies targeted to mechanism and/or therapy.
In this review I will describe these animal models as well as a new model my laboratory is
developing. Fatigue may be a subjectively defined state, but objective correlates can be
measured. Research has already produced some lines of evidence to help shape our
hypotheses of neurobiological substrates underlying fatigue, and I will review those data,
with particular emphasis on evidence for the importance of the circadian system in the
experience of fatigue.
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1. The human experience of fatigue
1.1 Defining fatigue
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It is critical for this work that we can define the state of fatigue, and yet that is a difficult
task. Researchers need to distinguish the way a healthy person experiences fatigue from the
cases where fatigue is a disabling symptom of poor health. It is important to listen carefully
to the ways people describe their experience of pathological fatigue, and to distinguish it
from non-pathological fatigue. Non-pathological fatigue would be the experience of being
tired after exercise, with energy restored after rest. Pathological fatigue is described as
having seven primary characteristics (Barsevick et al., 2010). It is subjective, and unusual
(not proportional to prior activity and not relieved by rest). Physical sensations range from
lassitude to exhaustion, and the fatigue has a negative impact on function (decreased
capacity for work, poor sleep quality, withdrawal from activities). There is decreased
cognitive ability and an unpredictable temporal course (the fatigue can be either chronic or
acute). The negative emotions associated with fatigue include helplessness, vulnerability,
impatience, anxiety, and emotional numbness (Barsevick et al., 2010). A definition of
cancer-related fatigue proposed by the working group ASCPRO (Assessing Symptoms of
Cancer Using Patient-Reported Outcomes) captures these attributes in defining fatigue as the

perception of unusual tiredness that varies in pattern or severity and has a negative impact
on ability to function (Barsecick et al., 2010). It is also important to distinguish fatigue from
depression, sleepiness, sickness, apathy, or other closely related or often co-morbid states.
Optimal would be a definition that allowed objective measures of the state, although we
might be content at this point if we can simply agree on a definition allowing consistent selfreport measures in human populations; unfortunately there is at this moment no agreement.
Current recommendations from systematic reviews suggest that the specific measurement
scale to use for assessment of fatigue should be selected for the specific clinical population
being studied (Elbers et al., 2011). In many cases a multidimensional scale is used, allowing
a multifaceted assessment that can capture the physical, affective and cognitive aspects of
this symptom. It may seem better practice to ask people to report only on their current state
of fatigue to avoid retrospective bias, but this can miss the variable temporal course, so
scales generally ask for a judgment on each item for some set reporting period (e.g., over the
past week) which varies across scales. Thus, with no agreement on the measurement device
Prog Neurobiol. Author manuscript; available in PMC 2013 November 01.
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it is difficult to compare studies assessing the rate of occurrence of the state, as well as the
impact of treatments, etc. While it is not the purpose of this review to sort this out, the
current state of affairs is impeding progress in the field and it would be better if researchers
could reach some consensus on measurement scales for assessing fatigue in human
populations.
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This review is focused on acute fatigue, with attention to central nervous system correlates
of fatigue. Researchers have differentiated "peripheral fatigue" and "central fatigue" (Cantor,
2010), although some question if this is a useful distinction (Gerber, 2010). Peripheral
fatigue presumably arises from muscle fatigue and fatigability while central fatigue is
thought to reflect central nervous system processes. The difficulty in making a clear
distinction arises from studies showing a role for the central nervous system in fatigue
initially thought to arise from the periphery. Both mental fatigue (increased cognitive effort,
difficulty sustaining attention) and physical fatigue (failing to initiate physical acts) can arise
from central nervous system derived fatigue (Chaudhuri and Behan, 2000). The focus in this
paper is on acute fatigue of the sort that might be triggered by a viral infection or radiation
therapy, and that may last well after the triggering event. Chronic fatigue syndrome is more
than simply the experience of fatigue in that it is defined by debilitating fatigue lasting 6
months or longer, along with other symptoms such as cognitive dysfunction, sleep
disturbance, myalgia, arthralgia, headache, gastrointestinal upset, sore throat and painful
lymph nodes (Christley et al., 2012).
1.2. Treatments for fatigue
Clinical assessments of fatigue must determine severity and then how much the fatigue
interferes with quality of life, including assessment of effect on social function, cognition,
mood, and physical function (Wang, 2011). Potential causes such as anemia, infection,
malnutrition, chronic pain, centrally acting drugs, etc. should be assessed. Fatigue may be
straightforward to treat if it can be ascribed to known causes. For example, fatigue might be
ascribed to anemia, malnutrition, hypothyroidism, infection, etc. Sleep disorders are linked
to self-reports of fatigue, and self-reports of fatigue are associated with both objective and
subjective measures of poor sleep (Liu et al., 2012). Clinicians will investigate to determine
if any likely causal factors can be identified and if so, if these factors lead to a treatment path
(Horneber et al., 2012).
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Yet many cases of fatigue are not easily treatable and in fact patients often assume that the
clinician will have no treatment and therefore they do not even bother to mention the
symptom of fatigue. Another complication in assessment arises when patients adapt to an
altered level of fatigue, defining that as the "new normal" and therefore begin to underreport fatigue ("response shifts"; Wang, 2011).
Treatments are limited, although exercise and cognitive behavior therapy have some benefits
(Price et al., 2008), as can psychostimulants (Horneber et al., 2012). Studies suggest lasting
benefits from aerobic exercise (averaging 75% of maximum heart rate for 3 h/week), and
possibly also benefits from anaerobic exercise and relaxation training (McNeely et al.,
2006). Cognitive behavioral therapy was shown to be effective in treatment of fatigue in
patients with multiple sclerosis (van Kessel et al., 2008). It appears that the critical
component of this therapy is the success in changing negative cognitions about fatigue, but
instead perceiving it as something that is time-limited and has less severe consequences
(Knoop et al., 2012). Cognitive behavioral therapy delivered via the internet was recently
shown to be more effective than usual care for adolescents with chronic fatigue syndrome
(Nijhof et al., 2012). Combining cognitive therapy with exercise is more beneficial than
cognitive therapy alone for post-stroke fatigue (Zedlitz et al., 2012). Modafinil was shown to
be effective in treating patients with severe cancer-related fatigue (Jean-Pierre et al., 2010),
Prog Neurobiol. Author manuscript; available in PMC 2013 November 01.
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and HIV-related fatigue (Rabkin et al., 2011) but was not effective for fatigue associated
with multiple sclerosis (Kos et al., 2008). Methylphenidate can be helpful in cases of cancerrelated fatigue (Horneber et al., 2012). A small trial indicated some benefit from light
therapy for fatigue in breast cancer patients (Ancoli-Israel et al., 2012). Serotonergic
antidepressant drugs have in several studies been reported to be ineffective to reduce
symptoms of fatigue even when they are effective for symptoms of depression (Morrow et
al., 2005). In support of this, people with hepatitis C treated with the cytokine IFN-α show
high incidence of fatigue and depression, with the depressive symptoms responding to
serotonergic antidepressants but the fatigue symptoms being resistant to this treatment
(Capuron and Miller, 2011).
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There are several "take-home" messages from this brief survey of current treatments. First,
we have some causes of fatigue that we can treat, such as anemia. In building animal models
we should screen for these causes in the same way we would with a patient presenting with
fatigue. Second, there is a scarcity of treatments in many cases of fatigue, with one of the
most effective, exercise, being difficult to administer to a patient suffering extreme fatigue.
Third, some treatments may help us to better understand the underlying mechanisms
generating pathological fatigue. For example, research on the success of cognitive
behavioral therapy in treatment of fatigue suggests that cognitions can worsen fatigue. This
will be a factor important in the human population that may not be able to modeled in
laboratory animals. On the other hand, lack of success of anti-depressants may point to
separable neural substrates for fatigue and depression, whereas the limited success of
stimulants may focus our research on the role of neural pathways activated by these
pharmacological agents.

2. Animal models of fatigue
An ideal animal model of fatigue would encompass as many attributes of the human
experience of fatigue as possible (strong face validity), while remaining specific to fatigue.
Using the seven unique characteristics of fatigue identified from a literature review of
conceptual definitions as summarizing in Barsevick et al. (2010), we can consider in the
broadest sense the range of measures an animal model might include (see Table 1). To
identify neural substrates underlying fatigue we would like to have an animal model that as
nearly as possible involves only the symptom of fatigue, without other closely associated
states.
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Second, an ideal animal model would also be induced by a stimulus that can induce fatigue
in humans (strong construct validity). Research on laboratory animals using reliable
measures of fatigue should allow us to determine further factors that can cause the
experience of fatigue.
Third, an ideal animal model would involve changes in behavior, cognition, or physiology
that are reversed by the same treatments that can reverse fatigue in people (strong predictive
validity). Of course we also hope that a strong animal model will allow us to discover novel
treatments for the relief of fatigue, but we validate the animal model first using what few
treatments are currently clinically employed.
We are in the early stages of establishing such a comprehensive animal model. Most of the
animal research reviewed below includes measures attempting to capture the physical
sensations associated with fatigue. The emotional and cognitive aspects of the human
experience of fatigue should be included in future research developing these models. Most
current models are based on an understanding of fatigue as arising from a pro-inflammatory
state. Very little current work can claim predictive validity for their animal model of fatigue.

Prog Neurobiol. Author manuscript; available in PMC 2013 November 01.
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Although it has been suggested that we could develop 4 types of animal models of fatigue
(Katafuchi et al., 2006), targeting physical fatigue (forced exercise, swimming), mental
fatigue, environmental fatigue (heat exposure), or immunologically induced fatigue, most
studies have used the latter, immunologically induced fatigue. Studies using forced exercise
and swimming run into difficulty separating the effects of the stress of the treatment and the
process of fatigue. For example, one group has studied rats subjected to electric shock and
either restraint stress or cold water swim on a daily basis for 23 days as a model for chronic
fatigue syndrome (Zou et al., 2010). This model is based in a conceptual understanding of
chronic fatigue syndrome as arising from stress, but might be better thought of as a model
for the study of effects of stress. Similarly involving stress, a model of fatigue based on
chronic sleep deprivation uses rats housed in a cage filled with water to about 2 cm (Tanaka
et al., 2003). On a perhaps milder note, one study measured grooming and rearing after a 5
min daily swim as a plausible model of post-exercise fatigue (Chao et al., 1992).
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Because chronic fatigue syndrome often starts after a flulike episode, suggesting a viral
cause, and other viruses are associated with lasting fatigue (eg, mononucleosis), some
researchers have developed animal models of fatigue using a virus. What may be one of the
most promising current models of fatigue involves systemic administration of polyinosinic:
polycytidylic acid (poly I:C), a synthetic analog of double-stranded RNA that mimics viral
infection. This treatment in rats induces a decrease in spontaneous wheel running persisting
about a week (see figure 1), and then gradually recovering over the next week (Katafuchi et
al., 2003). The acute response, such as a rise in body temperature, lasts only 24 h. Strikingly,
these rats do not show reduced levels of activity or exploration in the open field 7 d after
injection, even when voluntary wheel-running is greatly reduced. This suggests that they are
not impaired in motor activity in general or experiencing joint or muscle pain, and indicates
a possible effect more centrally on motivated activity. Changing to an icv route of
administration of poly I:C induces reductions in locomotor activity lasting at least 28 days
(Patro et al., 2010).
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Parasitic infections have also been used to model immunologically-induced fatigue in
rodents. Both Cryptosporidium parvum and Toxoplasma gondii infections cause a drop in
wheel running in mice lasting several weeks (Chao et al., 1992). Rats infected with the
parasite Trypanosoma brucei, associated in humans with human African trypanosomiasis or
"sleeping sickness", show reduced amplitude circadian activity rhythms, mirroring effects in
humans infected with this parasite who show diurnal somnolence and nocturnal insomnia
(Kristensson et al., 2010, Lundkvist et al., 2010). Activation of astrocytes and microglia as
well as increased levels of pro-inflammatory cytokines and the chemokine CXCL10 are
observed in the brains of rats infected with T.brucei (Bentivoglio et al., 2011).
Mice treated with killed Brucella abortus bacterial antigen showed a long lasting (e.g.,
several week) suppression in wheel-running, explained by an abbreviated duration of
activity rather than lasting changes in level of peak activity (Ottenweller et al., 1998). The
suppression of wheel-running activity lasted longer than signs of poor grooming. The
inducing injection appears to lead to a short-term illness that is followed by a long-lasting
state of fatigue, accompanied by changes in immunological markers (Ottenweller et al.,
1998), mirroring some of the most puzzling cases in humans where the inducing disease
seems to be in abeyance yet fatigue remains as a persistent symptom. On the other hand, a
recent report indicates that mice injected with B. abortus antigen can develop anemia over
10 days that recovers in 3–5 weeks, also showing a persistent increase in IL-6 (Sasu et al.,
2010). It is critical for future use of this model that the anemia be corrected and then the
mice tested to see if the suppression of activity is due to anemia or is separable from this.
This model has been extended in mice given 6 injections of killed B. abortus antigen over 12
Prog Neurobiol. Author manuscript; available in PMC 2013 November 01.
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weeks, with the animals then showing suppression of wheel-running lasting at least 7 weeks
after the last of 6 injections (Moriya et al., 2011). This modification offers an advantage of a
longer stable state following induction, allowing tests of treatments that might require some
time for beneficial action. It is hard on the animals; approximately one-third of the mice die
during the period of repeated injections (Chen et al., 2008; Moriya et al., 2011).
Injections of lipopolysaccaride (LPS), a bacterial endotoxin that can stimulate an innate
immune response, has been used to model “sickness behavior” (Dantzer, 2009), and fatigue
is one symptom among many. Acute sickness behavior lasts a day or so, but a central
response induced by peripheral stimuli can lead to proinflammatory cytokines being
elevated for months. In one study mice given a single injection of LPS showed increased
TNFα in the brain for 10 months, even when serum levels had returned to normal by 9 h
post-injection (Qin et al., 2007). This response was not observed in mice without the TNF
receptor, offering a control condition that should be useful in studies focused on the role of
central cytokines in fatigue. Another study showed activation of cortical microglia and
altered spine density up to one month post-LPS injection (Kondo et al., 2011).
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Other researchers have studied very low doses of LPS that can alter behavior without
inducing fever or signs of sickness. A sensitive behavior assay is that of burrowing; mice
will reliably empty a tube filled with material placed in their cage, but mice treated with
subpyrogenic doses of LPS show dramatic reductions in this activity (Teeling et al., 2007).
This effect on burrowing behavior could be blocked by pretreatment with a COX inhibitor,
indomethacin, suggesting a role for prostaglandins in mediating the effect.
Voluntary wheel-running is reduced following LPS administration and this effect depends in
part on peripherally increased IL-6 (Harden et al., 2011). Reduced social interaction
observed following LPS injection was shown to be due to IL-1β acting centrally in studies
using icv infusion of an antagonist to IL-1β (Konsman et al., 2008). Similarly, reduced
wheel-running in rats treated with LPS was reversed by a capsase-1 inhibitor icv, preventing
cleavage of pro-IL-1β to the active form, again implicating central IL1β in behavioral
manifestation of fatigue (Harden et al., 2011).
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In my laboratory we have begun to study rodents treated with IL-1β as a model of fatigue.
Prior work with clinical samples has shown associations between fatigue symptoms and
more stable downstream indicators of IL-1β activity (e.g. IL-1 receptor antagonist; Bower et
al., 2009, Schubert et al., 2007). Increased levels of IL-1 receptor antagonist are associated
with increased fatigue in women with breast cancer independent of associations with sleep
quality (Liu et al., 2012). Polymorphisms in the IL-1β gene predict fatigue in a small sample
of breast cancer survivors (Collado-Hidalgo et al., 2008). IL-1β can induce a cascade of
cytokine activity whereby other cytokines are increased in the brain and in the periphery
(Anisman et al., 2008). Increased IL-1β is predicted to increase other pro-inflammatory
cytokines, TNF-α and IL-6 and IL-18, as well as levels of IL-1 receptor antagonist
(Bandeen-Roche et al., 2009, Morley and Baumgartner, 2004). IL-1β leads to increased but
fragmented NREM sleep, and brain levels show diurnal changes with peak levels in the
sleep phase (Imeri and Opp, 2009, Ray et al., 2008). It has been demonstrated that mice
administered IL-1β over 5 days show reduced general locomotor activity and decreased
circadian variation in activity (Anisman et al., 2008)(see figure 2).
Shorter duration (circa one day) effects on locomotor activity are seen when TNF-α is
administered subcutaneously (Cavadini et al., 2007) or CD40 antibody is administered as a
model for autoimmune disorders (Taraborrelli et al., 2011). The response to CD40 antibody
was not observed in mice without TNF or the receptor TNFR1 indicating that this response
is more dependent on TNF than the other pro-inflammatory cytokines tested, IL-6 or IL-1β.
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Aging and neurodegenerative disorders could also be proposed as animal models of fatigue,
since they can involve the symptom of fatigue. They also share some level of centrally
increased cytokines and chemokines as well as activated microglia (Corona et al., 2012,
Perry, 2010). The peak amplitude and coherence of the wheel-running rhythm declines as
mice age, an effect seen in both wildtype and mice over-expressing alpha synuclein, a model
for Parkinson's disease. Over the age range studied, alpha synuclein over-expressing mice
showed decreased wheel-running with increased number of activity bouts as compared to
wildtype controls (Kudo et al., 2011a).
Researchers are just starting to develop models that will help us to better understand why
some people show vulnerability to developing fatigue and others are more resilient. For
example, mice previously exposed to murine gammaherpesvirus 68 showed prolonged signs
of fatigue following LPS injection, with reduced wheel running for 5 days following LPS
treatment in the previously infected group, a much more prolonged response than was seen
in the group given LPS without a pre-treatment (Olivadoti et al., 2011).
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What is common across many of these models is that fatigue appears to arise when some
stimulus induces increased proinflammatory cytokines in the brain and/or activated
microglia and increased expression of chemokines. A peripheral immune challenge is
thought to impact the central nervous system through several possible routes: by direct
cytokine transport across the blood-brain barrier, by stimulation of circumventricular organs
and choroid plexus cells to produce cytokines, by vagal nerve stimulation, or by direct
activation of brain vasculature (see Figure 3) (Dantzer et al., 2008). Cytokines are also
synthesized and released by neurons and glial cells of the CNS. A cytokine response to a
treatment such as an injection of poly I:C can be measured both peripherally and centrally
and is complex in terms of the number of cytokines increased and the time course
(Cunningham et al., 2007).
2.2 Suggestions for further validation and development of animal models of fatigue
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We can evaluate these animal models in terms of face validity (do they mirror the symptoms
of this state in humans?), construct validity (do the physiological mechanisms underlying the
model match those thought to underlie the human disorder?), and predictive validity (do the
treatments that reverse the symptom in humans also reverse the signs in the animal model?).
The models based on reduced wheel-running activity have good face validity in that the
measure of reduced voluntary physical exercise is reported in people with fatigue. This
behavior is also relatively easy to measure and quantify. In some cases researchers find
wheel-running decreased but other, less effortful, motor behaviors unchanged, and this
seems to be an especially attractive model of fatigue in terms of face validity. We can
definitely do more to increase face validity, as discussed below. Many of the above animal
models have construct validity if we accept that fatigue is the result of inflammation leading
to central increases in cytokines, chemokines and microglia activation. Future work can
extend this by including factors that are linked to increased susceptibility to fatigue, such as
gender and age. Predictive validity relies on having effective treatments; currently modafinil
and exercise offer the only somewhat supported possibilities in clinical populations. Little
progress has been made as yet in testing treatments and their ability to reverse effects in the
varied animal models.
We have several promising animal models to study fatigue, but we could develop these
further to increase their validity. First, it would be useful to include multiple measures to
better characterize effects. Particularly useful are measures of spontaneous effortful activity,
such as voluntary wheel-running or burrowing (Deacon, 2009). Studies should also include
less effortful locomotor activity that should be preserved at more normal levels (Katafuchi et
al., 2003, Olivadoti et al., 2011). It is important to note that wheel-running is not simply
Prog Neurobiol. Author manuscript; available in PMC 2013 November 01.
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another measure of locomotor activity. For example, mice bred for high levels of wheelrunning do not show changes in locomotor activity in an open-field (Bronikowski et al.,
2001) and mice bred for high levels of open field activity do not show changes in voluntary
wheel-running (DeFries et al., 1970). Wheel running is self-reinforcing, and many species
have demonstrated they are motivated to use a running wheel (Sherwin, 1998). It is not, as
some have assumed, a behavior chosen only because of the degraded laboratory
environment; animals in complex or seminatural environments will still choose to spend
considerable time in a running wheel (Sherwin, 1998). The rewarding and motivated aspect
of voluntary wheel running distinguishes this from open field activity (thought to reflect
response to novelty and exploration), forced treadmill running, or simply home cage
activity. Burrowing, a behavior measured in fewer studies, may be a similarly rewarding
motivated activity.
Clinical reports of fatigue include negative impacts on day-to-day functioning, unpleasant
emotions, and decreased cognitive abilities (see Table 1). This is a relatively unexplored
area in the animal models we have reviewed. While all patients do not experience all
symptoms, we should still be making an effort to include measures in our rodent studies that
could capture some of these aspects of the human experience of fatigue.

NIH-PA Author Manuscript
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Future research should carefully distinguish the specificity of these models. For example,
measures of sucrose preference, a common method to measure anhedonia, could suggest that
a drop in effortful activity does not arise from anhedonia. Measures of diurnal rhythms in
body temperature and daily distribution of sleep could be used to assess fever or sleep
disruption (e.g. Olivadoti et al., 2011). It would be helpful to clearly distinguish sleepiness
from fatigue. Sleep deprivation leads to increased theta power in the EEG (Vyazovskiy and
Tobler, 2005) and periods of reduced neural activity in cortical areas during waking
(Vyazovskiy et al., 2011). It would be interesting to investigate if immunologically-induced
fatigue or age-related fatigue are associated with similar neurophysiological changes as seen
with sleepiness. In other future research we could explore the possibility of other potential
factors such as allodynia, hyperalgesia, etc. mediating changes in behavior. Within a review
on assessment of fatigue in clinical populations the authors note "The investigator should
also measure other symptoms that could be confounded with cancer-related fatigue, such as
sleep disturbance; emotional distress; and/or depression, anorexia, and anemia."(Barsevick
et al., 2010). This is also true for animal models of fatigue. As much as possible,
investigators should try to assess the presence of each of these potential confounding
variables. An exemplary paper (Ray et al., 2011) includes hematology and serum cytokine
analysis at several time points post-treatment, as well as assessment of sleep disturbances,
food intake, and neurotoxicity screens within the context of an experiment comparing two
chemotherapeutic agents for effects on running-wheel activity.
Future work on this topic should consider effects of both gender and age, and potential
interactions between these important variables. Women are more likely to report having
fatigue, often report more severe fatigue (Torres-Harding and Jason, 2005), and are more
likely to seek medical help for their fatigue (Cope, 1992). Effects of aging on the immune
system are gender-specific (Goetzl et al., 2010). Self-reported fatigue is twice as prevalent in
older women than in men (Vestergaard et al., 2009). Permeability of the blood-brain barrier
may depend on age and gender (Bake and Sohrabji, 2004, Bake et al., 2009) possibly
leading to changes in neural response to peripheral inflammation (Dantzer, 2009). With age
comes increased risk for persistent fatigue (Clark et al., 1995). Aging is also associated with
chronic low-grade inflammation and increased levels of pro-inflammatory cytokines
(Ferrucci et al., 2005). Inflammation can lead to fatigue that is experienced as more severe
in older patients (Bautmans et al., 2010). A topic that has not yet been explored is whether
the etiology of fatigue differs with gender and/or age. A short-term inflammatory response
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has greater effects on activity levels and brain IL-1 β in aged (20–24 mo) mice (Abraham
and Johnson, 2009, Godbout et al., 2008). On the other hand, one study of male rats with
IL-1 β delivered directly into the brain icv reports that aged rats show diminished NREM
sleep response even when the induced fever was equivalent to that seen in younger rats
(Imeri et al., 2004). Exploration of fatigue beyond young adult male rats and mice, the
animal models dominating this and other fields (Beery and Zucker, 2011), could help us to
determine if the research we are conducting might be broadly relevant across multiple
species, ages and genders.

3. The neurobiology of fatigue
3.1 The neurobiology of voluntary wheel-running
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Running wheel activity likely arises from the activity of multiple neural networks. Recent
research demonstrates a role for neurons in the ventral tegmental area (VTA). In vivo
recordings from the VTA while mice ran in wheels demonstrated that non-dopaminergic
VTA neurons fire in a rhythmic pattern closely correlated with the running speed as well as
the cyclicity of limb movements during running (Wang and Tsien, 2011). Putative
dopaminergic VTA neurons also showed firing correlated with wheel use, but it was less
strongly correlated with the behavior, and more closely linked to the beginning and end of
the voluntary wheel running (Wang and Tsien, 2011). Researchers have demonstrated a
genetic basis for running wheel activity, in part by experiments involving selective breeding
of rats based on wheel revolutions, apparently selecting for speed of running rather than
duration (Knab and Lightfoot, 2010). The dopamine D1 receptor in the nucleus accumbens
(NAc), a major target for VTA neurons, plays a role in rats showing high levels of voluntary
wheel use (Roberts et al., 2011). The nucleus accumbens and dorsal striatum show high
levels of dopamine and dopamine metabolites in mice bred for high rates of wheel-running
even when mice were not allowed wheel access (Mathes et al., 2010). Polymorphisms in
dopamine receptor genes have been linked to levels of physical exercise in humans (Knab
and Lightfoot, 2010) supporting a link between dopamine and wheel running. Other brain
areas implicated in the neurobiology of wheel-running by studies using Fos staining were
the dentate gyrus of the hippocampus, the caudate-putamen, the prefrontal, medial frontal
and sensory cortex, and the lateral hypothalamus (Rhodes et al., 2003, Rhodes et al., 2005).
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Other neurotransmitters may also play a role. Several studies indicate the endocannabinoid
system mediates voluntary physical activity in part (De Chiara et al., 2010, Dubreucq et al.,
2010). In addition, orexin A can induce spontaneous locomotor activity (Teske et al., 2008,
Teske et al., 2010). Humans with narcolepsy, thought to be due to loss of brain orexin, show
high rates of fatigue, separable from the excessive daytime sleepiness that is also seen with
this disorder (Droogleever Fortuyn et al., 2012), suggesting orexin might play a role in the
neurobiology of fatigue.
Studies using animal models of fatigue have implicated the hippocampus, an area where Fos
induction was highly correlated with wheel-running (Rhodes et al., 2005). Rats given poly
I:C icv showed microglial activation in the hippocampus (Patro et al., 2010). Aged mice
treated with LPS showed disrupted memory consolidation and increased IL-1β expression in
hippocampus and cortex (Tarr et al., 2011). Infusion of IL-1β increased cytokine mRNA
expression in the hippocampus and prefrontal cortex of mice (Anisman et al., 2008). Mice
treated with repeated injections of killed B. abortus antigen show hippocampal atrophy
associated with reduced expression of brain-derived neurotrophic factor (BDNF) and
increased expression of acetylated p53 protein in the hippocampus (Moriya et al., 2011).
Decreased BrdU labeling and increased TUNEL labeling in these mice indicated reduced
hippocampal neurogenesis and increased apoptosis; however, these effects on the
hippocampus might be related to the stress of the repeated injections and immunological
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activation. Infusions of BDNF into the hippocampus did not alter level of locomotor activity
in an open field (Shirayama et al., 2002).
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Brain imaging of fatigued human subjects has provided little agreement to date of brain
regions mediating the experience of fatigue, but striatum and cortical areas often are
highlighted (DeLuca et al., 2009). Parkinson's patients with fatigue showed reduced
serotonin transporter binding in caudate, putamen, ventral striatum, and thalamus when
compared to similar patients without the symptom of fatigue (Pavese et al., 2010). Increased
lesion load is correlated with fatigue in multiple sclerosis, with studies suggesting a
functional cortical reorganization in response to the disease might underlie fatigue (Kos et
al., 2008). Signs of atrophy in the striatum, thalamus, frontal and parietal cortex were
observed in a sample of multiple sclerosis patients with fatigue (Calabrese et al., 2010).
Damage to the basal ganglia and internal capsule was predictive of post-stroke fatigue (Tang
et al., 2010). Interestingly, a new study indicates that lesions to the basal ganglia (striatum,
caudate/putamen, globus pallidus) change level of wakefulness and fragmented sleep in rats
(Qiu et al., 2010), supporting the suggestion from human brain imaging studies that this
brain region might play an important role in fatigue. Ventral striatum contains the nucleus
accumbens, discussed above in terms of mediating rewarding aspects of voluntary exercise.
3.2 The neurobiological correlates of fatigue: arousal, sleep/wake, reward systems
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Some studies suggest that the experience of fatigue is mirrored in the brain via changes in
circuits that control arousal and motivation. The ascending arousal system, one such circuit,
involves many lower brain areas providing excitatory drive to thalamus and cortex. This
system consists of multiple groups of neurons. Cholinergic neurons projecting to thalamus,
lateral hypothalamus (LH), basal forebrain (BF) and prefrontal cortex arise from the
peduculopontine tegmentum (PPT) and the laterodorsal tegmentum (LDT). Monoaminergic
cell groups project to the forebrain as well, including noradrenergic locus coeruleus (LC)
neurons as well as serotonergic medial and dorsal raphe neurons, and dopaminergic neurons
adjacent to the dorsal raphe. Histaminergic neurons in the tuberomammillary nuclei (TMN)
show similar projections and arousal-related firing patterns. These ascending projections
target thalamus, LH, BF, and cerebral cortex (especially the prefrontal cortex)(Saper et al.,
2010). Figure 4 outlines some of these circuits known to control arousal.
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The alternation between sleep and wake states involves switches in activity of several cell
groups within this system. Wakefulness is maintained by the orexin-containing neurons in
the LH; these neurons provide excitatory input to TMN neurons, serotonergic raphe nucleus
neurons, and noradrenergic LC neurons, as well as to the entire cerebral cortex. These
neurons receive inputs from many components of the ascending arousal system as well as
from prefrontal, amygdaloid, and VTA sites (Saper et al., 2010). Orexin neurons in the
lateral hypothalamus appear to be involved both in networks that maintain wake and also
those that mediate reward-seeking, such as those in the VTA (Aston-Jones et al., 2010), with
different neurons within the orexin-expressing group subserving these different functions.
Orexin neurons project to neurons in the VTA where they modulate the effects of prefrontal
cortex inputs to the dopamine-containing VTA neurons (Moorman and Aston-Jones, 2010).
Sleep is controlled in part by cells in the preoptic area (POA) that can inhibit cells in the
TM, raphe and LC (Rosenwasser, 2009). Cells in the ventrolateral preoptic area (VLPO)
appear to serve an "executive" function in inducing sleep (Rosenwasser, 2009). Following
lesions to VLPO neurons animals show less time asleep and more fragmented sleep bouts
(Lu et al., 2000).
Cytokines can directly influence these circuits. Both IL-1β and TNF-α regulate sleep in the
normal animal (Imeri and Opp, 2009) with levels in the brain increasing around the time of
day when the animal is likely to sleep. IL-1β directly inhibits wake-promoting neurons and
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stimulates sleep-promoting neurons in the POA and basal forebrain (BF) (Imeri and Opp,
2009). IL-1β inhibits serotonergic neurons of the dorsal raphe nuclei by enhancing the
effects of the inhibitory neurotransmitter GABA (Imeri and Opp, 2009). IL-1β also
stimulates 5-HT release from axon terminals in the POA which stimulates sleep and
serotonin stimulates IL-1β mRNA transcription in the hypothalamus, providing positive
feedback.
Studies using animal models have identified several of these brain regions as important in
effects of inflammation on neural circuits driving motor activity. For example, LPS-induced
acute suppression of motor activity (circa 1.5 h following LPS administration) was linked to
reduced activation in the dopaminergic VTA and histaminergic TMN and orexin neurons in
the LH (Gaykema and Goehler, 2011). Decreased serotonergic drive is implicated in another
model. Fatigue eight days following administration of poly I:C is accompanied by increased
IFN-α, p38 mitogen-activated protein kinase (MAPK), and serotonin transporter expression
in lateral POA and median preoptic area (MnPO) and as well as cortex (Katafuchi et al.,
2005). Microinjection of IFN-α into the prefrontal cortex led to a decrease in serotonin
levels (Katafuchi et al., 2006). Administration of the 5-HT1A agonist 8-OH-DPAT, but not
5-HT2, 5-HT3, or dopamine D3 agonists, was able to reduce the effect of poly I:C on wheelrunning. These studies point to many of the structures shown in Figure 4 as being altered in
the brain of an animal experiencing fatigue.
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3.3 Cytokine-induced suppression of circadian pacemaker output
Suppression of neural drive from the circadian clock could underlie chronic fatigue. It would
be expected that a muffled daily signal from the circadian pacemaker might lead to reduced
energy levels, impaired mental concentration and increased fatigue and fatigability. This
might also lead to loss of internal synchrony among brain areas normally expressing
circadian rhythms in neural activity, potentially impairing function of many brain regions.
Loss of synchrony among peripheral oscillators could bring about a general feeling of
malaise similar to that experienced during jet lag or rotating shift work. Loss of circadian
organization will impact metabolism and immune system function. Reduced locomotor
activity and/or disrupted sleep associated with feelings of fatigue could reduce the feedback
that locomotor activity normally provides to sculpt daily rhythmic output, further damping
rhythm output.
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Circadian rhythms are controlled by a pacemaker in the suprachiasmatic nuclei (SCN) in the
hypothalamus. A clinical report of a case study with damage to the circadian pacemaker in
the SCN suggests that such damage does leave a person feeling fatigued (Cohen and Albers,
1991). A study in squirrel monkeys indicates that SCN lesions reduce total wakefulness
(Edgar et al., 1993), suggesting the SCN may function to increase wakefulness during the
active period. The SCN may also function to increase sleep during the inactive period
(Mistlberger, 2005). Damage to the SCN in rats abolishes scale-invariant temporal patterns
in locomotor activity over scales of minutes to days (Hu et al., 2007), indicating the wide
influence of this small nucleus in coordinating activity of many other neural nodes. As can
be seen in Figure 5, the SCN is interconnected with regions important in regulating sleep/
wake, arousal, and reward discussed above. Projections from the suprachiasmatic nuclei
(SCN) reach both the wake-promoting neurons and the sleep-promoting systems by both
direct and indirect routes, relayed through the dorsomedial hypothalamus (DMH) and the
ventral subparaventricular zone (Rosenwasser, 2009). Lesions of the DMH, a major target of
SCN efferents, reduces total time awake (Chou et al., 2003). The neurons of the SCN also
project to orexin-containing neurons in the DMH and then to the LC, a structure that
modulates arousal by noradrenergic innervation of many regions including the frontal cortex
(Benca et al., 2009).The SCN projects to the VTA, likely via a relay in the MnPO, and a
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sub-population of VTA neurons shows diurnal modulation of firing rate (Luo and AstonJones, 2009); this circuit might mediate circadian regulation of reward-seeking.
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The SCN is responsive to cytokines. Receptors for IFN-γ are found in the ventrolateral SCN
of rats (Lundkvist et al., 1998), and in vitro studies show effects of LPS combined with
TNF-α and IFN-γ on excitatory postsynaptic activity and the amplitude of the circadian
rhythm in firing rate in rat SCN (Lundkvist et al., 2002). The cytokine TNF-α is able to
excite a subset of SCN neurons modulating the spontaneous firing and synaptic transmission
in the SCN (Nygard et al., 2009). The suppressors of cytokine signaling (SOCS) 1 and 3 are
also expressed in the mouse SCN (Sadki et al., 2007). Cells in the SCN express and respond
to several pro-inflammatory cytokines in an age-dependent manner (Beynon and Coogan,
2010, Cavadini et al., 2007, Kwak et al., 2008, Sadki et al., 2007).Injections of the cytokines
IFN-γ and TNF-α icv in mice elicits activation of SCN microglia (Bentivoglio et al., 2006).
LPS can induce a phase shift in mouse locomotor activity and the expression of c-Fos in the
SCN (Marpegan et al., 2005). Reduced amplitude circadian rhythms following infection
with simian immunodeficiency virus is associated with activated microglia in the
subparaventricular zone, a target for many SCN efferents (Huitron-Resendiz et al., 2007).
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In multiple neurological disorders where people report fatigue and animal models show
reduced locomotor activity, the SCN shows reduced levels of daytime firing rate and/or
reduced amplitude rhythm in spontaneous firing. For example, animal models for
Parkinson's disease (mice with over-expression of alpha-synuclein) show reduced amplitude
wheel-running rhythms and reduced firing rate recorded from the SCN but surprisingly little
change in the clock gene Per2 (Kudo et al., 2011a). Similar results were obtained in
transgenic mice expressing the entire human Huntington's Disease gene (Kudo et al.,
2011b). Rats infected with the parasite Trypanosoma brucei show reduced amplitude
circadian activity rhythms and the SCN spontaneous firing rate rhythm is dampened as well
(Lundkvist et al., 1998, Lundkvist et al., 2010).
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Older humans show alterations in the circadian timing system, including reduced amplitude
of rhythms (Monk et al., 1995, Munch et al., 2005). Healthy older adults show disruptions of
the pattern of sleep and wake which include difficulty initiating sleep, frequent night time
awakenings, early morning waking and high sleep propensity during the latter half of the
day (Bliwise, 1993). Aged mice show increased activated microglia and astrocytes in the
SCN both in control conditions and following icv injection of cytokines IFN-γ and TNF-α
(Deng et al., 2010). Aged animals show decreased amplitude rhythms of SCN electrical
activity (Nakamura et al., 2011, Satinoff et al., 1993, Watanabe et al., 1995) which some
researchers have proposed might be due to action of cytokines on the SCN (Coogan and
Wyse, 2008; see Figure 6).
Interestingly, studies of the genes driving circadian oscillators via transcription-translation
feedback loops (Ko and Takahashi, 2006) show only relatively minor alterations due to age
(Asai et al., 2001, Kolker et al., 2003, Nakamura et al., 2011), neurodegenerative disease
(Kudo et al., 2011a, Kudo et al., 2011b) or T. brucei infection (Lundkvist et al., 1998,
Lundkvist et al., 2010). A recent review suggested that, instead of molecular rhythms,
"neural activity rhythms in the SCN may be the 'weak link' of the circadian system"
(Colwell, 2011). Examples where the molecular clock seems to be functioning but neural
firing output is dampened suggest that we might be well advised to develop treatments that
boost cell firing from the SCN to better restore daily activity rhythms and normal levels of
locomotor activity in these populations.
However, while some cases of fatigue seem to involve suppression of neural firing but not
suppression of clock genes in the SCN, in other instances clock genes are clearly affected.
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For example, IFN-α has dramatic effects on clock genes in neurons of the SCN, suppressing
expression of key clock genes Clock, Bmal1, and Period (Koyanagi and Ohdo, 2002, Ohdo
et al., 2001). Injections of IFN-α or IFN-γ show a time-of-day-dependent effect on
circadian activity rhythm amplitude and clock gene expression in the SCN (Ohdo et al.,
2001). A different cytokine, TNF-α, suppresses expression of clock genes driven by E-box
promoters in fibroblasts (Cavadini et al., 2007); this may explain effects of CD40 antibody
as well as some aspects of LPS-driven immune activation (Okada et al., 2008, Taraborrelli et
al., 2011).

NIH-PA Author Manuscript

Interestingly, some cytokines may be produced by SCN cells, and function in clock output
pathways. For example, TGF-α is expressed at high levels in the SCN of Syrian hamster,
rats, mice, and rhesus macaques (Kramer et al., 2001, Li et al., 2002, Ma et al., 1994, Van
der Zee et al., 2005). TGF-α, infused into the third ventricle, reversibly inhibits locomotor
activity, an action thought to be mediated by the EGFR (ErbB-1) on hypothalamic neurons
(Kramer et al., 2001). A more long term TGF-α infusion leads to reversible inhibition of
grooming, exploring and feeding and to significant weight loss (Snodgrass-Belt et al., 2005).
EGFR is widely expressed in the brain and is present in the cells of the subparaventricular
zone, a major target for SCN efferents, just dorsal to the SCN (Kramer et al., 2001) as well
as in the SCN (Jobst et al., 2004, Van der Zee et al., 2005). Similar effects are reported for
neuregulin-1 that acts via the ErbB4 receptor (Snodgrass-Belt et al., 2005) and the
cardiotrophin-like cytokine, a cytokine in the IL-6 family that utilizes the gp130 receptor
(Kraves and Weitz, 2006). The current model is that these cytokines act as signaling
molecules that provide the daily signal for rest from the circadian pacemaker in the SCN.
Microglia activation leading to increased production of cytokines in the hypothalamus may
simply stimulate these circuits used by SCN neurons to drive rest.
Another important output molecule for the SCN is prokineticin 2 (PK2). This is synthesized
by SCN neurons and is found in many regions targeted by SCN efferents (Zhang et al.,
2009). Interestingly, deletion of either the PK2 gene or its receptor suppresses the amplitude
of circadian locomotor activity rhythms (Li et al., 2006, Prosser et al., 2007). Suppression of
SCN firing rate via tetrodotoxin reduces levels of PK2 in the SCN (Baba et al., 2008). Thus,
reduced cell firing will lead to reduced PK2 levels, which may then augment reductions in
locomotor activity. Cells in the SCN also express vasoactive intestinal polypeptide (VIP)
and vasopressin in output projections. Administration of LPS to the SCN brain slice induces
a dose-dependent increase in vasopressin release (Nava et al., 2000). VIP is important in
SCN cell coupling as well as SCN cell output (Vosko et al., 2007). Mice deficient in this
peptide show decreased locomotor activity, but daily voluntary exercise can help organize
the circadian rhythm in these mice (Hannibal et al., 2011, Power et al., 2010).
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4. Future directions
Future research will likely expand our understanding of the role of chemokines which are
highlighted in a few recent studies. Mice treated with poly I:C show upregulation of multiple
chemokines and their receptors across many brain areas, with the cerebellum particularly
sensitive (Fil et al., 2011). B. abortus can cause astrocyte proliferation and apoptosis,
secretion of pro-inflammatory cytokines and chemokines in the brain(Garcia Samartino et
al., 2010). We need to better understand what role chemokines play in modulating these
neural circuits underlying fatigue.
Stronger experiments to better establish some of the suggestions from the current literature
would provide more robust foundations for our understanding. The strongest evidence for an
important role of the circadian pacemaker in fatigue arises from several models (aging,
neurodegenerative disorders, T. brucei infection) and an immediate concern is to see these
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findings expanded to immunologically based models such as poly I:C or IL-1β treatments.
Tests of the necessary role of any specific brain area, as would be possible through targeted
infusions of an antagonist such as IL-1ra, will help researchers separate correlations from
causative changes.
Fatigue appears to be linked to CNS response to immune activation. To better treat fatigue
we might consider that it might be helpful to block the signal from peripheral immune
challenge that causes increased cytokines in the brain. In laboratory animals treatment with a
COX inhibitor, a capsase-1 inhibitor, or an IL-1β antagonist were able to reverse behavioral
signs of fatigue following LPS challenge (Harden et al., 2011, Konsman et al., 2008, Teeling
et al., 2007), suggesting that this might be an encouraging direction for future research. A
clinical trial testing a recombinant IL-1receptor antagonist as a potential treatment for
fatigue reported encouraging results in a post-hoc analysis, but the primary endpoint was not
statistically significant and the sample size was small (total n=26) (Norheim et al., 2012).
Further research into treatments is necessary.
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Can we treat fatigue better if we conceptualize it as arising from circadian dysregulation?
Fatigue in cancer patients is correlated with disrupted diurnal rhythms, reduced light
exposure during the day, and delayed phase, with some preliminary results indicating
benefits from light therapy (Ancoli-Israel et al., 2012). Light can have effects both from
being directly activating as well as from influencing circadian rhythms. New targets for
pharmacological therapies might include targets of SCN output pathways. Researchers could
work to develop ways to boost cell firing rate during the daytime in the SCN or to suppress
cell firing in this nucleus during the nighttime. We need to know what the effect of habitual
exercise has on SCN cell firing rhythms. A recent study showed effects of 8 weeks of
voluntary wheel-running on gene expression in the hippocampus(Kohman et al., 2011).
Researchers cannot yet say what genetic and environmental factors predispose people to
developing fatigue, but clearly some people are more susceptible than others. Interestingly,
chronic fatigue syndrome is associated with a polymorphism and increased expression of the
circadian clock gene NPAS2 (Smith et al., 2011). New research could examine human
fibroblasts from people with fatigue to determine if screening for circadian parameters is
helpful for diagnosis or treatment.
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The goal in studying a symptom is not to cure a disease; of course, fatigue is caused by
diverse disease processes. A full understanding of the causes of fatigue requires
consideration of the multitude of health and psychosocial factors and the relevance of
subject variables such as age and gender that can contribute to this symptom. We now can
research fatigue using a robust set of animal models, and we hope to find, regardless of
cause, common neurobiological substrates, research that should lead to better treatments.
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BF

basal forebrain

BDNF

brain-derived neurotrophic factor

DMH

dorsomedial hypothalamus

IGL

intergeniculate leaflet

LH

lateral hypothalamus

LDT

laterodorsal tegmentum

LPS

lipopolysaccaride

LC

locus coeruleus

MnPO

median preoptic area

MAPK

mitogen-activated protein kinase

MUA

multiple unit activity

NE

noradrenergic

NAc

nucleus accumbens

NTS

nucleus of the solitary tract

PPT

peduculopontine tegmentum

PAG

periaqueductal gray

poly I:C

polyinosinic: polycytidylic acid

POA

preoptic area

PK2

prokineticin 2

sPVZ

sub-paraventricular zone

SCN

suprachiasmatic nuclei

SOCS

suppressors of cytokine signaling

TMN

tuberomammillary nuclei

VIP

vasoactive intestinal polypeptide

VTA

ventral tegmental area

VLPO

ventrolateral preoptic area
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•

Fatigue is a common symptom of many disorders but with few effective
treatments.

•

Fatigue can be studied with animal models.

•

Activation of brain microglia or increased cytokines is associated with fatigue.

•

The neural network includes regions for arousal, sleep, reward, and circadian
rhythms.

•

Research on neural targets may allow development of novel treatments for
fatigue.
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Figure 1.

Suppression of spontaneous wheel-running activity following poly I:C. Male Wistar rats
were administered poly I:C (P; 3mg/kg) or saline (S) and killed on day 1 or day 8 following
injection. Total daily wheel-running activity was expressed as a percentage of baseline.
(N=5/group; from Katafuchi et al., 2005).
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Figure 2.

Infusion of IL-1β suppresses motor activity in mice. Male CD-1 mice were given either
vehicle or IL-1β (2µg/day) via osmotic mini-pump for 7 days (N=16/group) and home cage
motor activity was measured. Activity is shown as mean ± SEM in 12 h epochs
corresponding to the light and dark portions of the LD cycle. From Anisman et al., 2008.
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Figure 3.

Schematic of peripheral immune challenge routes to brain. Peripheral signals of
inflammation can take 4 main routes to influence the nervous system. Some cytokines are
transported directly across the blood-brain barrier. Others stimulate cells in the
circumventricular organs and choroid plexus to produce cytokines that diffuse into the brain.
IL-1 can stimulate receptors on macrophages and endothelial cells associated with the
cerebral vasculature, and these stimulate the release of prostaglandin E2. Finally, peripheral
signals can directly activate the vagal nerve, which can alter brain response via a relay in the
nucleus of the solitary tract (NTS).
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Figure 4.

Neuroanatomical areas important in the ascending arousal system. This system consists of
noradrenergic neurons of the locus coeruleus (LC), cholinergic neurons of the
pedunculopontine and lateraodorsal tegmental nuclei (LDT, PPT), serotonergic neurons in
the raphe nuclei, dopaminergic neurons in periaqueductal gray (PAG), histaminergic
neurons of the tuberomammaillary nucleus (TM), orexin-containing neurons of the lateral
hypothalamus (LH) and basal forebrain (BF) neurons containing GABA and acetylcholine.
(based on Fuller et al., 2006; brain image from Allen Brain Atlas).
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Figure 5.
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SCN connections to sleep circuits. Several select afferent inputs to the SCN are shown, the
photic input via the retina and inputs from raphe nuclei and intergeniculate leaflet (IGL) that
appear to have more to do with mediating influences of activity or arousal on the SCN.
Many efferents from the SCN terminate in the sub-paraventricular zone (sPVZ) and then
converge with direct efferents on cells in the dorsomedial hypothalamus (DMH). Both direct
and indirect SCN efferents impact the VLPO, where GABAergic neurons play an important
role in inducing sleep. Indirect SCN efferent pathways target the LH where orexincontaining neurons help switch to a state of wake. Cells in the DMH target the LC where
noradrenergic (NE) neurons help maintain arousal. Outputs from the SCN indirectly
impinge on the VTA to modify reward circuits.
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Figure 6.

Older animals show reduced amplitude SCN neural firing and reduced locomotor activity.
Neural firing recorded in vivo (multiple unit activity, MUA) and locomotor activity of
young (A) and middle aged (15±2 months) mice (B). Top bars indicate light (open) and dark
(shaded) lighting conditions. Integrated mean MUA activity for each age group is shown in
C and D. (N=4/group; from Nakamura et al., 2011).
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Characteristics of fatigue in humans common to many definitions (from Barsevick et al., 2010) and
suggestions of how these might be translated to an ideal animal model of fatigue.
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Characteristic

Descriptors from studies of
humans

Possible translation to rodent
model

Subjective

assessed by self-report

Unable to translate this to rodent model

Physical sensation

"exhaustion, decreased energy, weakness, malaise,
tiredness, lassitude"

Decreased spontaneous wheel-running activity,
decreased burrowing, changes in spontaneous
locomotor activity

Unusual

"unrelieved by rest", "not proportional to activity,
unpredictable"

Symptoms that are different from those of control
animals

Impact on functioning

"decreased capacity for work, decreased quality of life,
difficulty completing tasks, poor sleep quality, withdrawal
from activities, debilitation"

Altered sleep, shortened duration of circadian
active phase, decreased social interactions

Unpleasant emotions

"helplessness, vulnerability, distress, reactivity,
impatience, anxiety, emotional numbness, unpleasant
experience, emotional lability"

Altered performance on learned helplessness
tasks, changes in tests of anxiety such as the
elevated plus maze

Decreased cognitive ability

"decreased attention, decreased concentration, decreased
motivation, memory deficits, decreased mental capacity,
decreased capacity for mental work"

Deficits in tests of attention, cognition,
motivation, memory

Temporal variability

"pervasive, chronic, acute, persistent, episodic"

Unrestrictive in terms of the temporal course
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